{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:57:02Z","timestamp":1787601422483,"version":"build-2736575974"},"reference-count":77,"publisher":"Informa UK Limited","issue":"2","funder":[{"name":"the National Institutes of Health National Institute on Drug Abuse","award":["DA25267"],"award-info":[{"award-number":["DA25267"]}]},{"DOI":"10.13039\/100007131","name":"Texas Tech University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007131","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ohio Northern University-Raabe College of Pharmacy"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1080\/13543776.2024.2446230","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T09:24:36Z","timestamp":1737019476000},"page":"165-180","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Patent review of novel compounds targeting opioid use disorder (2018\u20132024)"],"prefix":"10.1080","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9644-0750","authenticated-orcid":false,"given":"Samuel","family":"Obeng","sequence":"first","affiliation":[{"name":"Texas Tech University Health Sciences Center","place":["Amarillo, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance R.","family":"McMahon","sequence":"additional","affiliation":[{"name":"Texas Tech University Health Sciences Center","place":["Amarillo, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4345-788X","authenticated-orcid":false,"given":"Edward","family":"Ofori","sequence":"additional","affiliation":[{"name":"Ohio Northern University","place":["Ada, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,1,26]]},"reference":[{"issue":"11","key":"e_1_3_5_3_1","first-page":"766","article-title":"Pharmacologic therapy for acute pain","volume":"87","author":"Blondell RD","year":"2013","unstructured":"Blondell RD, Azadfard M, Wisniewski AM. Pharmacologic therapy for acute pain. Am Fam Physician. 2013;87(11):766\u2013772.","journal-title":"Am Fam Physician"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.36076\/ppj.2008\/11\/S105"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0137-5"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32279-7"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/0193841X07307315"},{"key":"e_1_3_5_8_1","unstructured":"CDC-NCHS. U.S. Overdose deaths decrease in 2023 first time since 2018. [Internet]. 2024 [cited 2024 May 21]. Available from: https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2024\/20240515.htm"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108350"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-062613-093100"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000193"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028019828954"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2016.1100960"},{"key":"e_1_3_5_14_1","unstructured":"Kruegel A Sames D Javiitch J et al. inventors; The trustees of Columbia University in the city of New York the research foundation for mental hygiene inc. Sloan-Kettering Institute for Cancer research assignee. Deuterated mitragynine analogs as safer opioid modulators in the mitragynine class. WIPO patent WO 2020160280A1. 2020 Aug 06."},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.6b00360"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.120.000189"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01111"},{"key":"e_1_3_5_18_1","unstructured":"Haile CN Kosten TA Das J. inventors; University of Houston Systems assignee. Combination of Mitragynine and naltrexone for substance use disorders. WIPO patent WO2024\/076660A1. 2024 Apr 11."},{"key":"e_1_3_5_19_1","unstructured":"Zhang Y. inventors; Virginia Commonwealth University assignee. Non-peptide opioid receptor modulators for treatment of opioid abuse and addiction alcoholism and neurological disorders associated with opioid receptors. WIPO patent WO 2020041159A1. 2020 Feb 27."},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm301247n"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01158"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm801272c"},{"key":"e_1_3_5_23_1","unstructured":"Zhang Y inventor; Virginia Commonwealth University assignee. Naltrexamine derivatives bearing 5-member heterocyclic ring systems as opioid receptor modulators. WIPO patent WO 2023163969 A3. 2023 Oct 5."},{"key":"e_1_3_5_24_1","unstructured":"German N Hossain MA. inventors; texas tech university system assignee. Novel opioid antagonists and methods related thereto. US patent 20200131183A1. 2020 Apr 30."},{"key":"e_1_3_5_25_1","unstructured":"German N Neugebauer V Hossain MA et al. inventors; Texas tech university system as- signee. Novel selective kappa opioid receptor antagonists and methods related thereto for treatment of addiction and neuropathic pain. WIPO patent WO 2020092996A1. 2020 May 7."},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115309"},{"key":"e_1_3_5_27_1","unstructured":"Medina JC Nerurkar A Sadlowski C et al. Inventors; Epiodyne inc. assignee. Opioid receptor modulators. WIPO patent WO 2022\/216750 A1. 2022 Oct 13."},{"key":"e_1_3_5_28_1","unstructured":"Rice KC Jacobson A Sulima A et al. inventors; US health assignee. Selective opioid receptor agonists and antagonists. WIPO patent WO 2024\/026350A1. 2024 Feb 1."},{"key":"e_1_3_5_29_1","unstructured":"Brents L Tobacyk J Crooks P et al. inventors; Bio ventures LLC assignee. Deuterated buprenorphine as a protective agent for fetal subjects against full-agonist opioid exposure. WIPO patent 2024\/036337A2. 2024 Feb 15."},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.118.254219"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(24)29586-0"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12012-016-9366-y"},{"key":"e_1_3_5_33_1","unstructured":"Sames D Hemby S Havel V. inventors; The trustees of Columbia University in the city of New York high point University assignee. Oxa-ibogaine analogues for treatment of substance use disorders. WIPO patent WO 2022178099A1. 2022 Aug 25."},{"key":"e_1_3_5_34_1","unstructured":"Sames D Havel V Hwu C. inventors; The trustees of columbia university in the city of New York assignee. Ibogaine analogs as therapeutics for neurological and psychiatric disorders. WIPO patent WO 2022020352A1. 2022 Jan 27."},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.2c00214"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2017.1310218"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2017.1320802"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.71"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0099-9598(01)56006-X"},{"key":"e_1_3_5_40_1","unstructured":"Dolmetsch RCE Gasparini F Gomez-Mancilla B. inventors; Novartis A.G. assignee use of mGlur5 antagonists. WIPO patent WO 2022013809 A2. 2022 Jan 20."},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/FBP.0b013e3282f18d58"},{"key":"e_1_3_5_42_1","unstructured":"Kuesters E Acemoglu M Lustenberger P et al. inventors; Novartis A.G. assignee. Processes for the preparation of 4-oxo-octahydro-indole-1-carbocylic acid methyl ester and derivatives thereof. WIPO patent WO 2022013809A2. 2010 Feb 18."},{"key":"e_1_3_5_43_1","unstructured":"Gasparini F Auberson Y Ofner S. inventors; Novartis A.G. novartis pharma gmbh. Gasparini Fabrizio Auberson Yves Ofner Silvio assignee. Acetylene derivatives having mGluR 5 antagonistic activity. CA patent 2732095A1. 2003 Jun 12."},{"key":"e_1_3_5_44_1","unstructured":"Imbert B Sung V Dolmetsch RE et al. inventors; Tempero Bio Inc. assignee. Methods of treating substance use disorder with 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 negative allosteric modulators 2023. WIPO patent 2023\/249789A1. 2023 Dec 28."},{"key":"e_1_3_5_45_1","unstructured":"Newman AH Kumar V Shaik AB inventors; The United States of America as represented by the Secretary department of health and human services assignee. Dopamine D3 receptor selective Antagonists\/Partial agonists and uses thereof. United States patent US 12097196B2. 2020."},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-328X(97)00025-9"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-018-0284-5"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.259390"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.04.003"},{"key":"e_1_3_5_50_1","unstructured":"Newman AH Bonifazi A Battiti FO. inventors; The United States of America as represented by the Secretary department of health and human services assignee. Dual-target Mu opioid and dopamine D3 receptors Ligands; preparation and use thereof. WIPO patent WO 2022187206A1. 2024 Sep 09."},{"key":"e_1_3_5_51_1","unstructured":"Laezza F Zhou J Chung JM et al. inventors; The board of regents of the university of texas system assignee. Novel non-opioid Anti-Pain medication. WIPO patent WO 2020154679. 2020 Jul 30 p. A1."},{"key":"e_1_3_5_52_1","unstructured":"Booth R. Inventor; Northeastern University assignee. Serotonin receptor modulators. WIPO patent WO 2022040395A2. 2022 Feb 24."},{"key":"e_1_3_5_53_1","unstructured":"Rovati LC. Inventor; rottapharm biotech S.R.L. assignee. Use of 2-phenyl-6-(1h-imidazol-1-yl) quinazoline for the prevention of abuse and of side effects of at least one opioid. WIPO patent WO2021104639. 2021 Jun 3 p. A1."},{"key":"e_1_3_5_54_1","unstructured":"Blahunka P Gerard M Mototsugu I. inventors; Astellas pharma global dev inc assignee. Methods of treating substance use disorder. WIPO patent WO 2023028519 A2. 2023 Mar 2."},{"key":"e_1_3_5_55_1","unstructured":"Shiraishi N Hoshii H Hamaguchi W et al. inventors; Astellas pharma inc. assignee. Sulfur-containing bicyclic compound. USPTO patent US 9051339 B2. 2013 Jun 9."},{"key":"e_1_3_5_56_1","unstructured":"Kozikowski A Tueckmantel W. inventors; Bright minds bioscienes assignees. Azepinoindoles and methods of preparation thereof 2023. WIPO patent WO 2023\/212811. 2023 Nov 9 p. A1."},{"key":"e_1_3_5_57_1","unstructured":"Flaherty DP Watts VJ Dwyer TS et al. inventors; Purdue research foundation assignee. Pyrazolyl pyrimidinone compounds and the uses thereof. US patent 20230250084 A1. 2023 Aug 10."},{"key":"e_1_3_5_58_1","unstructured":"Wang W Prisinzano T Uhl G et al. inventors; The Us gov as represented by the department of veterans affairs Wang Wei Prisinzano Thomas; assignee. PTPRD inhibitors and uses thereof. WIPO patent WO 2022232694A1. 2022 Nov 3."},{"key":"e_1_3_5_59_1","unstructured":"Zhan C Zheng F. inventors; Univ kentucky res found assignee. Butyrylcholinesterase inhibitors for treatment of opioid use disorder. US patent 20200368224A1. 2020 Nov 26."},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(83)90616-1"},{"key":"e_1_3_5_61_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3565(25)32246-9","article-title":"Hydrolysis of diacetylmorphine (heroin) by human serum cholinesterase","volume":"215","author":"Lockridge O","year":"1980","unstructured":"Lockridge O, Mottershaw-Jackson N, Eckerson HW, et al. Hydrolysis of diacetylmorphine (heroin) by human serum cholinesterase. J Pharmacol Exp Ther. 1980;215:1\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_5_62_1","unstructured":"Polymeropoulos MH Birznieks GP inventors; Vanda pharmaceuticals inc. university of kentucky research foundation assignee. Method of treatment with tradipitant. WIPO patent WO 2019236852A1. 2019 Dec 12."},{"key":"e_1_3_5_63_1","unstructured":"Felts A Han C Capstick R et al. inventors; Univ Vanderbilt assignee. Arylsulfonyl derivatives and their use as muscarinic acetylcholine receptor M5 inhibitors. WIPO patent 2021\/257977A1. 2021 Dec 23."},{"key":"e_1_3_5_64_1","unstructured":"Lindsley W Jones KC Conn PJ et al. inventors; Univ Vanderbilt assignee. Competitive and noncompetitive inhibitors of the muscarinic acetylcholine receptor M5. WIPO patent 2021237038 A1. 2021 Nov 25."},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.162371899"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.8b00481"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00192"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109424"},{"key":"e_1_3_5_69_1","unstructured":"Lopez DA Gross GM. inventors; Pannex therapeutics inc assignee. Pannexin-1 modulators and methods of treating disorders in which pannexin-1 is implicated. WIPO patent WO 2024049929 A2. 2024 Mar 7."},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2017.07.001"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.prcp.20180006"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.8826"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-018-0292-5"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108511"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1212785"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2017.19.3\/gkoob"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cobeha.2014.09.004"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301119"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(16)00104-8"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2024.2446230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T04:03:13Z","timestamp":1738382593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2024.2446230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,26]]},"references-count":77,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1080\/13543776.2024.2446230"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2024.2446230","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-08-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}